Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

Annals of Internal Medicine

Volumn 129, Issue 1, 1998, Pages 36-38

  Gitlin, Norman ^a,b   Julie, Neil L ^a,c   Spurr, Charles L ^a,c   Lim, Kie N ^a,b   Juarbe, Herbert M ^a,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROGLITAZONE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; ESSENTIAL HYPERTENSION; FEMALE; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TOXICITY; PRIORITY JOURNAL;

EID: 0032125406     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-1-199807010-00008     Document Type: Article

References (4)

1. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-93.
2. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996;39:701-9.
3. Lee WM. Review article: drug-induced hepatotoxicity. Aliment Pharmacol Ther. 1993;7:477-85.
4. Farrell GC. Drug-induced Liver Disease. London: Churchill Livingstone; 1994: 247-300.